Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 2/20 | 0.58 |
| ▸ | MRGPRX4 | Q96LA9 | 5/20 | 0.46 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.44 |
| ▸ | CYP11B1 | P15538 | 2/20 | 0.44 |
| ▸ | CYP11B2 | P19099 | 2/20 | 0.44 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.44 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.44 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.44 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.44 |
| ▸ | PTGER1 | P34995 | 1/20 | 0.43 |
| ▸ | PPIA | P62937 | 1/20 | 0.43 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.43 |
| ▸ | AR | P10275 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17630139 | 0.83 | CYP11B1 (0.50) | CYP19A1CYP11B1CYP11B2 | |
| SCHEMBL70797 | 0.83 | MAOB (0.60) | MAOBMRGPRX4CYP19A1CYP11B1CYP11B2 | |
| SCHEMBL23882866 | 0.82 | APP (0.53) | MAOBCYP19A1AR | |
| SCHEMBL6431004 | 0.81 | MAOB (0.58) | MAOBMRGPRX4CYP19A1CYP11B1CYP11B2 | |
| SCHEMBL20302267 | 0.81 | MAOB (0.58) | MAOBMRGPRX4CYP19A1CYP11B1CYP11B2 | |
| SCHEMBL6061295 | 0.81 | MAOB (0.58) | MAOBMRGPRX4CYP19A1CYP11B1CYP11B2 | |
| SCHEMBL31715781 | 0.81 | MAOB (0.57) | MAOBFFAR1 | |
| SCHEMBL6766128 | 0.80 | MAOB (0.57) | MAOBMRGPRX4AR | |
| SCHEMBL3490042 | 0.80 | MAOB (0.57) | MAOBMRGPRX4AR | |
| SCHEMBL2570360 | 0.80 | CYP19A1 (0.62) | MAOBMRGPRX4CYP19A1CYP11B1CYP11B2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060106048-A1 | Furoisoquinoline derivative and use thereof | PASCALI, PETROS P. (CY) | 2006-05-18 | — | — | US | disclosed |
| EP-1541576-A1 | FUROISOQUINOLINE DERIVATIVE AND USE THEREOF | Takeda Pharmaceutical Company Limited (JP) | 2005-06-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060106048-A1 | Furoisoquinoline derivative and use thereof | PDE3B, PDE2A, PDE3A | MAOB 274/4885MRGPRX4 216/4885CYP19A1 238/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.